Skip to main content

Table 1 Simple linear regression estimates producing estimates of incremental values (i.e., Δ’s)

From: Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial

Regression

Subgroup

Simple Linear Regression Estimates of Incremental Net Benefit (p-values)

Effect

(in QALYs)

Cost

(in $)

NB($0)

(amount by which benefits outweigh costs, when an extra QALY is worth $0)

NB($50 k)

(amount by which benefits outweigh costs, when an extra QALY is worth $50,000)

NB($100 k)

(amount by which benefits outweigh costs, when an extra QALY is worth $100,000)

NB($200 k)

(amount by which benefits outweigh costs, when an extra QALY is worth $200,000)

NB($300 k)

(amount by which benefits outweigh costs, when an extra QALY is worth $300,000)

NB($400 k)

(amount by which benefits outweigh costs, when an extra QALY is worth $400,000)

NB($500 k)

(amount by which benefits outweigh costs, when an extra QALY is worth $500,000)

KRAS-MUT

(n = 150)

−0.0172

(0.4158)

13,787

(< 0.001)

− 13,787

(< 0.0001)

− 14,650

(< 0.0001)

−15,514

(0.0007)

−17,240

(0.0573)

−18,966

(0.1664)

−20,692

(0.2601)

−22,418

(0.3308)

KRAS-WT

(n = 216)

0.1769

(< 0.001)

30,843

(< 0.001)

−30,843

(< 0.0001)

−21,999

(< 0.0001)

− 13,154

(0.0013)

4536

(0.5734)

22,226

(0.0715)

39,916

(0.0167)

57,606

(0.0062)

ALL

(n = 527)

0.0771

(0.0011)

22,210

(< 0.001)

−22,210

(< 0.0001)

−18,358

(< 0.0001)

−14,507

(< 0.0001)

−6805

(0.1789)

898

(0.9080)

8600

(0.4129)

16,303

(0.2186)

  1. Note: The p-value is reported in parenthesis below the coefficient estimate. This two-sided p-value is converted to a 1-sided p-value [20] to make the cost-effectiveness acceptability curve (CEAC) in Figure 2